Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
Portfolio Pulse from
Incyclix Bio has announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate the combination of INX-315, Verzenio (abemaciclib), and fulvestrant in HR+/HER2- breast cancer. This collaboration aims to explore the potential of INX-315 as a best-in-class CDK2 inhibitor.
November 18, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has entered into a collaboration with Incyclix Bio to evaluate a new combination therapy for HR+/HER2- breast cancer, involving its drug Verzenio. This could enhance Verzenio's market position if successful.
The collaboration with Incyclix Bio to test a new combination therapy involving Verzenio could lead to expanded use and market share for Verzenio if the trials are successful. This is a positive development for Eli Lilly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80